LINCOLNPharmaceuticals
Lincoln Pharmaceuticals Ltd — Profit & Loss Statement
₹564.95
-2.30%
Lincoln Pharmaceuticals Ltd Profit & Loss Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Tax Effect Of Unusual Items | 0.00 | 0.00 | 1.30 Cr | 0.79 Cr | — |
| Tax Rate For Calcs | 0.25 | 0.24 | 0.27 | 0.28 | — |
| Normalized EBITDA | 123.97 Cr | 134.33 Cr | 106.53 Cr | 102.10 Cr | — |
| Net Income From Continuing Operation Net Minority Interest | 82.35 Cr | 93.30 Cr | 72.90 Cr | 69.36 Cr | — |
| Reconciled Depreciation | 12.90 Cr | 10.62 Cr | 9.17 Cr | 8.09 Cr | — |
| Reconciled Cost Of Revenue | 291.32 Cr | 278.34 Cr | 243.09 Cr | 219.79 Cr | — |
| EBITDA | 123.97 Cr | 134.33 Cr | 111.28 Cr | 104.95 Cr | — |
| EBIT | 111.07 Cr | 123.71 Cr | 102.12 Cr | 96.86 Cr | — |
| Net Interest Income | -1.88 Cr | -1.46 Cr | 4.14 Cr | 3.58 Cr | — |
| Interest Expense | 1.88 Cr | 1.46 Cr | 1.64 Cr | 0.92 Cr | — |
| Normalized Income | 82.35 Cr | 93.30 Cr | 69.45 Cr | 67.29 Cr | — |
| Net Income From Continuing And Discontinued Operation | 82.35 Cr | 93.30 Cr | 72.90 Cr | 69.36 Cr | — |
| Total Expenses | 534.64 Cr | 491.26 Cr | 424.28 Cr | 379.80 Cr | — |
| Diluted Average Shares | 2.00 Cr | 2.00 Cr | 2.00 Cr | 2.00 Cr | — |
| Basic Average Shares | 2.00 Cr | 2.00 Cr | 2.00 Cr | 2.00 Cr | — |
| Diluted EPS | 41.11 | 46.58 | 36.40 | 34.63 | — |
| Basic EPS | 41.11 | 46.58 | 36.40 | 34.63 | — |
| Diluted NI Availto Com Stockholders | 82.35 Cr | 93.30 Cr | 72.90 Cr | 69.36 Cr | — |
| Net Income Common Stockholders | 82.35 Cr | 93.30 Cr | 72.90 Cr | 69.36 Cr | — |
| Otherunder Preferred Stock Dividend | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Income | 82.35 Cr | 93.30 Cr | 72.90 Cr | 69.36 Cr | — |
| Net Income Including Noncontrolling Interests | 82.35 Cr | 93.30 Cr | 72.90 Cr | 69.36 Cr | — |
| Net Income Continuous Operations | 82.35 Cr | 93.30 Cr | 72.90 Cr | 69.36 Cr | — |
| Tax Provision | 26.84 Cr | 28.94 Cr | 27.58 Cr | 26.58 Cr | — |
| Pretax Income | 109.19 Cr | 122.24 Cr | 100.48 Cr | 95.94 Cr | — |
| Other Non Operating Income Expenses | 22.48 Cr | 34.42 Cr | 22.47 Cr | 10.00 Cr | — |
| Net Non Operating Interest Income Expense | -1.88 Cr | -1.46 Cr | 4.14 Cr | 3.58 Cr | — |
| Interest Expense Non Operating | 1.88 Cr | 1.46 Cr | 1.64 Cr | 0.92 Cr | — |
| Operating Income | 88.59 Cr | 89.28 Cr | 80.68 Cr | 88.40 Cr | — |
| Operating Expense | 243.32 Cr | 212.93 Cr | 181.19 Cr | 160.01 Cr | — |
| Other Operating Expenses | 117.96 Cr | 99.40 Cr | 34.53 Cr | 29.57 Cr | — |
| Depreciation And Amortization In Income Statement | 12.90 Cr | 10.62 Cr | 9.17 Cr | 8.09 Cr | — |
| Depreciation Income Statement | 12.90 Cr | 10.62 Cr | 9.05 Cr | 7.95 Cr | — |
| Gross Profit | 331.91 Cr | 302.21 Cr | 261.87 Cr | 248.41 Cr | — |
| Cost Of Revenue | 291.32 Cr | 278.34 Cr | 243.09 Cr | 219.79 Cr | — |
| Total Revenue | 623.23 Cr | 580.55 Cr | 504.95 Cr | 468.20 Cr | — |
| Operating Revenue | 623.23 Cr | 580.55 Cr | 504.95 Cr | 468.20 Cr | — |
| Total Unusual Items | — | 22.45 Cr | 4.75 Cr | 2.85 Cr | 2.79 Cr |
| Total Unusual Items Excluding Goodwill | — | 22.45 Cr | 4.75 Cr | 2.85 Cr | 2.79 Cr |
| Interest Income | — | 7.02 Cr | 6.17 Cr | 5.03 Cr | 2.24 Cr |
| Rent Expense Supplemental | — | 0.24 Cr | 0.17 Cr | 0.94 Cr | 0.14 Cr |
| Special Income Charges | — | -0.30 Cr | -0.26 Cr | -0.83 Cr | -0.18 Cr |
| Other Special Charges | — | 0.30 Cr | 0.26 Cr | 0.13 Cr | 0.18 Cr |
| Total Other Finance Cost | — | 0.52 Cr | 0.39 Cr | 0.53 Cr | 0.36 Cr |
| Interest Income Non Operating | — | 7.02 Cr | 6.17 Cr | 5.03 Cr | 2.24 Cr |
| Amortization | — | 0.11 Cr | 0.11 Cr | 0.14 Cr | 0.14 Cr |
| Selling General And Administration | — | 41.25 Cr | 37.95 Cr | 35.44 Cr | 34.91 Cr |
| Selling And Marketing Expense | — | 23.35 Cr | 18.04 Cr | 16.82 Cr | 20.39 Cr |
| General And Administrative Expense | — | 17.91 Cr | 19.91 Cr | 18.63 Cr | 14.52 Cr |
| Rent And Landing Fees | — | 0.24 Cr | 0.17 Cr | 0.94 Cr | 0.14 Cr |
| Write Off | — | — | — | 0.70 Cr | 0.00 |
| Minority Interests | — | — | — | — | -0.03 Cr |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Lincoln Pharmaceuticals Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.